Event

Alberto Papi

MD
Univ Di Ferrara;Univ Di Ferrara Centro Asma;University of Ferrara

Hélène Prunier

MSc
Chiesi Farmaceutici

Mario Scuri

MD, PhD
Chiesi Farmaceutici

Annamaria Muraro

MS
Chiesi Farmaceutici

Alessandro Guasconi

MSc
Chiesi Farmaceutici

Leonardo M. Fabbri

MD
Univ of Ferrara;University of Ferrara

Stefano Petruzzelli

MD, PhD
Chiesi Farmaceutici;Chiesi Farmaceutici S.p.a.

Stefano Vezzoli

MSc
Chiesi Farmaceutici

Dave Singh

MD, NP
Manchester Academic Health Science Centre, The University of Manchester;Medicines Evaluation Unit (MEU), University of South Manchester NHS Foundation Trust;The University of Manchester, University Ho

Single Inhaler Extrafine Triple Therapy Reduces Clinically Important Deterioration (CID) in COPD Compared to Indacaterol/Glycopyrronium: Post-Hoc Analysis of the TRIBUTE Study